2,6-dibromo-4-iodoanisole | 704909-77-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2,6-dibromo-4-iodoanisole
• 英文别名: 2.6-Dibrom-4-jod-1-methoxy-benzol；2,6-Dibrom-4-jod-anisol；Methyl-(2.6-dibrom-4-jod-phenyl)-aether；1,3-dibromo-5-iodo-2-methoxybenzene
• CAS: 704909-77-3
• 化学式: C₇H₅Br₂IO
• 分子量: 391.829
• InChiKey: RLTMDWOLFGTLDZ-UHFFFAOYSA-N

物化性质

• 熔点：
  78 °C
• 沸点：
  328.3±42.0 °C(Predicted)
• 密度：
  2.334±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,6-dibromo-4-iodoanisole 在 palladium diacetate 盐酸 、 sodium tetrahydroborate 、 copper(l) iodide 、 四甲基乙二胺 、 三溴化硼 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 42.0h， 生成 methyl 4-bromo-5-hydroxy-1H-indole-2-carboxylate
  参考文献：
  名称：

  Palladium-Catalyzed Regioselective Hydrodebromination of Dibromoindoles:  Application to the Enantioselective Synthesis of Indolodioxane U86192A

  摘要：

  A novel approach to the selective preparation of 4-bromoindoles was developed via Pd(OAc)(2)/rac-BINAP catalytic reactions. A variety of 4,6-dibromoindoles were transformed to 4-bromoindoles with high regioselectivity. This methodology, along with C-N and C-O bond-forming reactions developed in our laboratory, was applied to the enantioselective synthesis of indolodioxane U86192A, an antihypertensive agent.

  DOI：

  10.1021/jo035819k
• 作为产物：
  描述：

  2,6-二溴苯酚 在 N-碘代丁二酰亚胺 、 potassium carbonate 作用下， 以 丙酮 、 乙腈 为溶剂， 反应 7.0h， 生成 2,6-dibromo-4-iodoanisole
  参考文献：
  名称：

  Palladium-Catalyzed Regioselective Hydrodebromination of Dibromoindoles:  Application to the Enantioselective Synthesis of Indolodioxane U86192A

  摘要：

  A novel approach to the selective preparation of 4-bromoindoles was developed via Pd(OAc)(2)/rac-BINAP catalytic reactions. A variety of 4,6-dibromoindoles were transformed to 4-bromoindoles with high regioselectivity. This methodology, along with C-N and C-O bond-forming reactions developed in our laboratory, was applied to the enantioselective synthesis of indolodioxane U86192A, an antihypertensive agent.

  DOI：

  10.1021/jo035819k

文献信息

• [EN] COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES<br/>[FR] COMPOSÉS, COMPOSITIONS ET PROCÉDÉS COMPRENANT DES DÉRIVÉS D'IMIDAZOLE ET DE TRIAZOLE
  申请人：INST ONEWORLD HEALTH

  公开号：WO2010033626A1

  公开（公告）日：2010-03-25

  The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-3 or encompassed by formulas (I), (IA), (IB), (II), and (III)) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

  本发明涉及用于治疗动物疾病的组合物和方法，该疾病对通过向需要的哺乳动物投与本文中定义的化合物的有效量（包括表1-3中列出的那些化合物或由公式（I）、（IA）、（IB）、（II）和（III）所包含的化合物）或其组合物来抑制功能性囊性纤维化跨膜传导调节蛋白（CFTR）多肽作出反应，从而治疗该疾病。本发明特别涉及一种治疗腹泻和多囊肾病的方法。
• Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives
  申请人：Doyle Kevin James

  公开号：US20090318429A1

  公开（公告）日：2009-12-24

  The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-14 or encompassed by formulas I-XII) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

  本发明涉及用于治疗动物患病的组合物和方法，该疾病对通过向需要的哺乳动物投予本文所定义的化合物的有效量（包括表1-14中列出的那些化合物或被I-XII公式所包含的化合物）或其组合物来抑制功能性囊性纤维化跨膜传导调节蛋白（CFTR）多肽作出反应，从而治疗该疾病。本发明特别涉及一种治疗腹泻和多囊性肾病的方法。
• Compounds, compositions and methods comprising heteroaromatic derivatives
  申请人：Doyle Kevin James

  公开号：US20100144733A1

  公开（公告）日：2010-06-10

  The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-14 or encompassed by formulas I-XII) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

  本发明涉及用于治疗动物体内对抑制功能性囊性纤维化跨膜传导调节因子（CFTR）多肽敏感的疾病的组合物和方法，通过向需要治疗该疾病的哺乳动物中投与本文所定义的化合物的有效量（包括表1-14中列出的化合物或公式I-XII所包含的化合物）或其组合物，从而治疗该疾病。本发明特别涉及治疗腹泻和多囊肾病的方法。
• COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES
  申请人：Jones Graham Peter

  公开号：US20110237528A1

  公开（公告）日：2011-09-29

  The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-3 or encompassed by formulas (I), (IA), (IB), (II), and (III)) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

  本发明涉及用于治疗动物疾病的组合物和方法，该疾病对抑制功能性囊性纤维化跨膜传导调节因子（CFTR）多肽敏感，通过向需要的哺乳动物施用本文中定义的化合物的有效量（包括表1-3中列出的化合物或被公式（I）、（IA）、（IB）、（II）和（III）所包含的化合物）或其组合物，从而治疗该疾病。本发明特别涉及治疗腹泻和多囊肾病的方法。
• Gold‐Catalyzed Arylative Cope Rearrangement
  作者：Bidisha Paroi、Chayanika Pegu、Manoj V. Mane、Nitin T. Patil

  DOI：10.1002/anie.202406936

  日期：2024.8.12

  Reported herein is the arylative Cope rearrangement of 1,6-heptadienes facilitated by ligand-enabled redox gold catalysis. Unlike the classical Cope rearrangement involving 1,5-hexadienes, a cyclization-induced [3,3]-rearrangement of 1,6-heptadienes using the merger of π-activation and cross-coupling reactivity, has been achieved.

  本文报道了由配体驱动的氧化还原金催化促进的 1,6-庚二烯的芳基化 Cope 重排。与涉及 1,5-己二烯的经典 Cope 重排不同，利用 π 激活和交叉偶联反应性的合并，实现了环化诱导的 1,6-庚二烯的 [3,3]-重排。